ov 1

This alpha-helical antimicrobial OV-1 ovispirin peptide derived from SMAP29 peptide.It was found to inhibit several antibiotic-resistant bacterial strains including mucoid and nonmucoid Pseudomonas aeruginosa.

Carboplatin (JM-8) is a cisplatin derivative, a DNA synthesis inhibitor. Carboplatin binds to DNA, inhibits replication and transcription, and induces cell death. Carboplatin has antitumor activity.

Poziotinib hydrochloride irreversibly inhibits EGFR (HER1 or ErbB1), including EGFR mutants, HER2, and HER4, thereby inhibiting the proliferation of tumor cells that overexpress these receptors. It is an orally bioavailable, quinazoline-based pan epidermal growth factor receptor (EGFR or HER) inhibitor with potential antineoplastic activity.

Vactosertib Hydrochloride (EW-7197 Hydrochloride) is an orally active and highly efficient ATP-competitive ALK5 (activin receptor-like kinase 5) inhibitor, a TGF-β receptor I inhibitor with anti-metastatic and anticancer properties. It sensitizes pancreatic cancer cells to gemcitabine by inhibiting their viability.

Poziotinib (NOV120101)(NOV120101; HM781-36B) is an irreversible HER1/2/4 inhibitor (IC50s: 3/5/23 nM).

Tipranavir is a protease inhibitor that inhibits HIV-1 resistant to more than 1 protease inhibitor .Tipranavir effectively inhibits HIV-1 protease enzyme activity and dimerisation and has potent activity against multiple protease inhibitor (PI) HIV-1 isolates (IC50 of 66-410 nM). Tipranavir inhibits SARS-CoV-2 3CLpro activity.

DOV-102677 is a psychoactive drug being developed by Merck and is currently in clinical trials. It is a triple reuptake inhibitor, or serotonin-norepinephrine-dopamine reuptake inhibitor. It is the-enantiomer of DOV-216,303, and its-enantiomer is DOV-21,947.

Fasoracetam monohydrate is a small synthetic molecule and a metabotropic glutamate receptor activator, which has previously undergone extensive Phase I-III clinical trials in humans for vascular dementia.

Farletuzumab ecteribulin is an antibody-drug conjugate (ADC) consisting of the humanized antibody farletuzumab, which targets the folate receptor alpha (FRA), with an antibody-to-drug ratio of 4.0. In vitro, farletuzumab ecteribulin exhibits cytotoxic and antitumor activity against FRA-positive cells.

Bebtelovimab (LY-CoV1404) is a neutralizing, fully human IgG1 monoclonal antibody targeting the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. This product binds specifically to a highly conserved epitope on the RBD, blocking the interaction between the spike protein and the human angiotensin-converting enzyme 2 (ACE2) receptor. Bebtelovimab exhibits potent and broad neutralizing activity against various SARS-CoV-2 variants, including Omicron (BA.1/BA.2), Delta, and other earlier strains. In clinical settings, it is utilized to reduce the risk of severe disease progression in high-risk ambulatory patients, such as solid organ transplant recipients.

BTYNB (MDK6620) is an inhibitor of the oncofetal mRNA-binding protein IMP1 (IC50 = 5 μM for IMP1 binding to c-Myc mRNA). MDK6620 downregulates β-TrCP1 mRNA and reduces activation of nuclear transcriptional factors-kappa B (NF-κB). It disrupts this enhancer function by impairing IGF2 mRNA-binding protein 1 (IGF2BP1)-RNA association

Venadaparib (NOV140101) (IDX-1197) is a potent, selective and orally active PARP inhibitor with IC50s of 1.4 nM and 1.0 nM for PARP1 and PARP2, respectively. Venadaparib is insensitive to PARP-5. Venadaparib prevents the repair of DNA single-strand breaks (SSBs) and can be used in solid tumor research.

PF-00835231 is a CoV-2 cysteine 3C-like protease (3CLpro) inhibitor, with IC50s of 0.27 nM and 4 nM for SARS CoV-2 and SARS CoV-1 3CLpro, respectively. PF-00835231 is the active compound of the first anti-3CLpro regimen in clinical trials.

YH-53 is a potent peptidomimetic 3CLpro inhibitor featuring a unique benzothiazolyl ketone pharmacophore that displays low-nanomolar inhibition of SARS-CoV-1 and SARS-CoV-2 main proteases and effectively blocks SARS-CoV-2 replication, thereby providing a structurally distinctive and mechanistically validated compound for antiviral and COVID-19 research.

SFN68 is a humanized IgG1 neutralizing monoclonal antibody targeting HGF. It significantly inhibits the interaction between HGF and c-Met, the activation of c-Met, and HGF-mediated cell scattering and proliferation. SFN68 is applicable for cancer research.

NVP-BQS481 (Compound 1) is a selective inhibitor of spindle motor protein 5 (Eg5), with an IC50 of less than 0.5 nM. It demonstrates significant anti-mitotic and anti-tumor activities, exhibiting an IC50 of 0.09 nM against SK-OV-3ip cells. NVP-BQS481 is suitable for use as a cytotoxic payload in the synthesis of antibody-drug conjugates (ADCs).

Antitumor agent-61 (Compound 9b), an Irinotecan (Ir) derivative, demonstrates potent anticancer activity with IC50 values ranging from 0.92 to 3.23 μM against six human cancer cell lines: SK-OV-3, SK-OV-3/CDDP, U2OS, MCF-7, A549, and MG-63, and specifically induces apoptosis in SK-OV-3 cells via mitochondrial pathways [1].

Glucozaluzanin C, a lignan extracted from the MeOH extract of Ainsliaea acerifolia (Compositae) roots, demonstrates ED50 values of 2.45 μg/mL for A549 cells, 1.37 μg/mL for SK-OV-3 cells, 0.40 μg/mL for SK-MEL-2 cells, 1.41 μg/mL for XF498 cells, and 1.43 μg/mL for HCT15 cells, respectively [1].

Norcepharadione B shows good inhibitory activity against the replication of HSV-1, it also shows antimalarial activity with EC50 values of 7.5mug/ml. Norcepharadione B exhibits significant cytotoxicity against five human tumor cell lines (A-549, SK-OV-3,

8-epi-Helenalin, a sesquiterpene lactone with anti-tumor properties, is derived from Inula britannica L. var. chinensis (Rupr.) Reg. It demonstrates cytotoxic activity against a range of cancer cell lines, with ED50 values of 12.2 μM for HL-60, 53.8 μM for A549, 9.1 μM for MCF7, 8.7 μM for HCT-15, 18.7 μM for SK-OV-3, and 8.3 μM for Malme-3M, indicating its potential for anti-tumor research [1].